Why is Multidrug-Resistant Pseudomonas aeruginosa a Priority Pathogen?

I Atanaskovic - Import mechanism of Pyocin G, folded protein antibiotic active against P. aeruginosaПодробнее

Treatment of multidrug resistant Pseudomonas aeruginosa infections | 32nd ICCПодробнее

Hovakim Grabski - Breaking the Wall of Antibiotic Resistant Pseudomonas aeruginosaПодробнее

Pseudomonas aeruginosa | Pathogenesis | identification and treatmentПодробнее

Restoring The Power of Fosfomycin with Antibiotic Adjuvants: In silico ScreeningПодробнее

Evolutionary drivers of antibiotic resistance in Pseudomonas aeruginosa (CCDD ID Epi Seminar Series)Подробнее

Treatment of Resistant Pseudomonas Aeruginosa InfectionsПодробнее

Prof Yehuda Carmelli New and old drugs to combat multidrug resistant Gram negativesПодробнее

Multistate Outbreak of Antimicrobial-Resistant Pseudomonas AeruginosaПодробнее

Pseudomonas aeruginosa - an Osmosis PreviewПодробнее

Pseudomonas Infections: Selecting Upfront AntibioticsПодробнее

Infections with Multidrug-Resistant Organisms (MDROs)Подробнее

New Treatments on the Horizon for Pseudomonas InfectionsПодробнее

Antibacterial drugs: Clinical development for non-developers, part 2 – Single pathogensПодробнее

Why Are Pseudomonas Infections Getting Harder to Treat?Подробнее

What are the Limitations of Current Drugs to Treat Pseudomonas Infections?Подробнее

Antibiotic resistance and the rise of the 'superbug'Подробнее

Pseudomonas aeruginosa and Potential Exposure RisksПодробнее

Pseudomonas Continues to Acquire Resistance, Complicating TreatmentПодробнее

Pseudomonas Infections: Prognoses & Treatment ApproachesПодробнее

Pseudomonas Infections in the ICU: Who's Susceptible?Подробнее